-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] China is a major diabetes country in the wor.
According to relevant data, the number of diabetic patients in China will exceed 140 million in 202It is estimated that by 2045 there will be more than 174 million people with diabet.
The large patient population is driving the global direct cost of diabetes to continue to gr.
According to the Frost & Sullivan report, the global market for type 2 diabetes alone has reached US$70 billi.
At present, insulin is an important drug for diabetic patients to control blood sugar and has an irreplaceable position in diabetes treatme.
In recent years, with the deepening of understanding of diabetes, China's insulin market is also expanding, and more and more domestic companies have begun to deploy in this fie.
Recently, Gan & Lee Pharmaceuticals announced that it has received the "Notice of Approval for Clinical Trials of Drugs" issued by the State Food and Drug Administration regarding the company's drug under development GZR10 The acceptance number is CXSL2200110 and the notification number is 2022LP078According to the data, GZR101 is a dual-insulin compound preparation prepared by mixing the long-acting basal insulin GZR33 and fast-acting insulin aspart under research by Gan & Lee Pharmaceutica.
It is intended to be used for the treatment of diabet.
Degu Aspart Double Insulin Injection, a subsidiary of Degu, was approved for marketing in China in May 2019, and its trade name in China is Novo Plu.
Degludec aspart double insulin injection is a double insulin premixed preparation that mixes long-acting insulin degludec and fast-acting insulin aspart in a ratio of 7:In January this year, NMPA issued an approval document showing that Wanbang Pharmaceutical's insulin lispro injection has also been approved for marketing, becoming the second domestic compa.
Previously, only Lilly and Gan & Lee's insulin lispro was approved for marketing in Chi.
The data show that the original research of insulin lispro is Humalog developed by Eli Lilly, and the analogues are closer to biological insulin secretion in terms of onset time, peak time and duration of acti.
Humalog was approved to be marketed in China in 2005, and then it consists of mixed insulin protamine zinc recombinant insulin lispro mixed injection (25R) (trade name Humalog 25), protamine zinc recombinant insulin lispro mixed injection (50R) (trade name Humalog 50) has gradually entered Chi.
In addition to the above companies, Tonghua Dongbao is also developing insulin lispro injection, which has just started Phase III clinical trials in December 202Specifically, on December 27, 2021, Tonghua Dongbao announced the acceptance of the clinical trial application for soluble glargine lispro diinsulin (BC Combo) injection (THDB0207 injection) issued by the Center for Drug Evaluation of the State Drug Administrati.
Notice, the acceptance number is CXSL2101513 count.
From the above point of view, the research and development of innovative insulin drugs in China is ushering in an upsur.
The industry expects that, with the help of policies, the development of the domestic insulin industry will accelera.
It is understood that in 2019, the State Council issued the "Healthy China Action (2019-2030)", which listed diabetes prevention and control actions as one of the 15 major actio.
Diabetes management has received more and more attention from the Chinese governme.
With the concerted efforts, the domestic diabetes drug market is about to usher in great chang.
However, it should be noted that, under the policy of normalized procurement with volume and the consistency evaluation policy of generic drugs, the domestic diabetes generic drug market competition is gradually entering a white-hot, popular varieties such as sitagliptin and acarbose have more than ten A company was approved for listi.
The increasing competition for popular targets is forcing domestic companies to move from generic drugs to Fast-follow and First-in-cla.
At present, in addition to the three domestic innovative diabetes drugs, Benaglutide Injection, Macrogolloxenatide Injection, and Siglitatide Sodium Tablets, the domestic pharmaceutical companies have accelerated their research and developme.
Leading innovative drugs have entered the clin.
For example, the ultra-long-acting antibody drug independently developed by Hongyun Huaning, which is administered once every two weeks and directly acts on the GLP-1 receptor, is in clinical phase III and is expected to become a new generation of ultra-long-acting hypoglycemic agen.
and weight loss medicatio.
Hua Medicine's self-developed dozagliatin is the world's first glucokinase activator (GKA) diabetes treatment drug to submit a new drug marketing applicati.
Powerf.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
According to relevant data, the number of diabetic patients in China will exceed 140 million in 202It is estimated that by 2045 there will be more than 174 million people with diabet.
The large patient population is driving the global direct cost of diabetes to continue to gr.
According to the Frost & Sullivan report, the global market for type 2 diabetes alone has reached US$70 billi.
At present, insulin is an important drug for diabetic patients to control blood sugar and has an irreplaceable position in diabetes treatme.
In recent years, with the deepening of understanding of diabetes, China's insulin market is also expanding, and more and more domestic companies have begun to deploy in this fie.
Recently, Gan & Lee Pharmaceuticals announced that it has received the "Notice of Approval for Clinical Trials of Drugs" issued by the State Food and Drug Administration regarding the company's drug under development GZR10 The acceptance number is CXSL2200110 and the notification number is 2022LP078According to the data, GZR101 is a dual-insulin compound preparation prepared by mixing the long-acting basal insulin GZR33 and fast-acting insulin aspart under research by Gan & Lee Pharmaceutica.
It is intended to be used for the treatment of diabet.
Degu Aspart Double Insulin Injection, a subsidiary of Degu, was approved for marketing in China in May 2019, and its trade name in China is Novo Plu.
Degludec aspart double insulin injection is a double insulin premixed preparation that mixes long-acting insulin degludec and fast-acting insulin aspart in a ratio of 7:In January this year, NMPA issued an approval document showing that Wanbang Pharmaceutical's insulin lispro injection has also been approved for marketing, becoming the second domestic compa.
Previously, only Lilly and Gan & Lee's insulin lispro was approved for marketing in Chi.
The data show that the original research of insulin lispro is Humalog developed by Eli Lilly, and the analogues are closer to biological insulin secretion in terms of onset time, peak time and duration of acti.
Humalog was approved to be marketed in China in 2005, and then it consists of mixed insulin protamine zinc recombinant insulin lispro mixed injection (25R) (trade name Humalog 25), protamine zinc recombinant insulin lispro mixed injection (50R) (trade name Humalog 50) has gradually entered Chi.
In addition to the above companies, Tonghua Dongbao is also developing insulin lispro injection, which has just started Phase III clinical trials in December 202Specifically, on December 27, 2021, Tonghua Dongbao announced the acceptance of the clinical trial application for soluble glargine lispro diinsulin (BC Combo) injection (THDB0207 injection) issued by the Center for Drug Evaluation of the State Drug Administrati.
Notice, the acceptance number is CXSL2101513 count.
From the above point of view, the research and development of innovative insulin drugs in China is ushering in an upsur.
The industry expects that, with the help of policies, the development of the domestic insulin industry will accelera.
It is understood that in 2019, the State Council issued the "Healthy China Action (2019-2030)", which listed diabetes prevention and control actions as one of the 15 major actio.
Diabetes management has received more and more attention from the Chinese governme.
With the concerted efforts, the domestic diabetes drug market is about to usher in great chang.
However, it should be noted that, under the policy of normalized procurement with volume and the consistency evaluation policy of generic drugs, the domestic diabetes generic drug market competition is gradually entering a white-hot, popular varieties such as sitagliptin and acarbose have more than ten A company was approved for listi.
The increasing competition for popular targets is forcing domestic companies to move from generic drugs to Fast-follow and First-in-cla.
At present, in addition to the three domestic innovative diabetes drugs, Benaglutide Injection, Macrogolloxenatide Injection, and Siglitatide Sodium Tablets, the domestic pharmaceutical companies have accelerated their research and developme.
Leading innovative drugs have entered the clin.
For example, the ultra-long-acting antibody drug independently developed by Hongyun Huaning, which is administered once every two weeks and directly acts on the GLP-1 receptor, is in clinical phase III and is expected to become a new generation of ultra-long-acting hypoglycemic agen.
and weight loss medicatio.
Hua Medicine's self-developed dozagliatin is the world's first glucokinase activator (GKA) diabetes treatment drug to submit a new drug marketing applicati.
Powerf.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
